Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Swine Influenza Daily Update: 20 July 2009, Wales
The NPHS influenza surveillance scheme, which records reports of diagnoses of flu from more than 300 GP practices across Wales, shows low but increasing levels of influenza activity across Wales. Further detail can be found on the NPHS website: click here.
generic viagra online
Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
News of the day
Those From Homeless Families More Likely To Suffer Mental Health Problems
A new multisite study by UCLA and RAND Corp. researchers and colleagues has found that 7 percent of fifth-graders and their families have experienced homelessness at some point in their lives and that the occurrence is even higher - 11 percent - for African American children and those from the poorest households.
Nutrition

Paladin Labs Announces Canadian Launch Of Twinject(R) TwinpackTM For Anaphylaxis

Good news for the 1.3 million Canadian patients at risk for anaphylaxis, as Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, announced the Canadian launch of Twinject® TwinpackTM, making it more convenient for people to manage this potentially life threatening condition. Twinject® TwinpackTM includes two Twinject® epinephrine auto-injectors, allowing patients to store an auto-injector in multiple key locations such as home or work, while carrying another device with them at all times. The TwinpackTM also includes a Twinject® demonstrator that helps patients and family members practice using the auto-injector so they feel more confident in an emergency anaphylactic situation. "It"s vital for individuals at risk for anaphylaxis to be prepared for an emergency", says Laurie Harada, Executive Director, Anaphylaxis Canada. This requires having an auto-injector with them at all times and making sure they and others, such as friends, family members, and caregivers, are comfortable using the device. The demonstrator provides an important hands-on teaching tool." The need for effective anaphylaxis management is clear, with published studies demonstrating that fewer than 30 per cent of patients carry their epinephrine auto-injectors with them at all times(1). In addition, a recent survey shows that 39 per cent to 50 per cent of food-induced anaphylactic reactions in children occurred outside the home(2). "We are excited to launch the Twinject® TwinpackTM as it addresses the needs of anaphylactic patients. As such, the Twinject® TwinpackTM will provide superior protection for patients and ensure that they are adequately trained and prepared in an anaphylactic situation," said Mark Beaudet, Vice President Sales and Marketing of Paladin Labs. Twinject® is a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis). Twinject® TwinpackTM is available in two dosages (0.3 mg and 0.15 mg) for self-administration. About Anaphylaxis Anaphylaxis is a severe, life-threatening systemic allergic reaction triggered by exposure to one or more various antigens, including foods, insect stings, drugs, and latex products. Up to eight percent of children have food allergies, with allergies to peanuts and tree nuts among children having doubled in the past five years. The timing, location, pattern (including onset, severity and length) and specific treatment requirements for each future anaphylactic episode cannot be predicted in advance. It is estimated by Anaphylaxis Canada that there are over 1.3 million Canadians at risk for anaphylaxis. About Twinject® Twinject® is a pre-filled, pen size auto-injector with two doses of epinephrine for the emergency treatment of severe allergic reactions (anaphylaxis). The first dose is administered using the auto-injector. The second dose, if needed, is administered via a pre-filled syringe located inside the barrel of the device. Twinject® is available in a compact, crush-resistant carrying case, with instructions for use attached to the device. In addition, a consumer campaign called Twinject® BeReady, is available to provide comprehensive patient training and support. For more information about Twinject®, please visit http://www.twinject.ca. (1) Goldberg A, Confino-Cohen R. J Allergy Clin Immunol 2000;106(6):1184-1189 (2) Jarvinen KM, et al. J Allergy Clin Immunol 2008;122(1):133-138 Paladin Labs Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009